Built to help voters verify how officials vote using official public records — non-partisan, no spin, no jargon.
H.R. 1518 · 119th Congress

New Era of Preventing End-Stage Kidney Disease Act

In committee

See what this could mean for your district

Save your district in Account to view district-specific context for this bill.

Bill details

Introduced: 2/24/2025
Current status: In committee
Bill ID: 119hr1518
Latest official action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Bill overview

A neutral overview based on official congressional sources.

Introduced in House

New Era of Preventing End-Stage Kidney Disease Act This bill establishes regional centers of excellence, postgraduate fellowships, and training for health professionals relating to the diagnosis and treatment of rare kidney disease. It also requires the Department of Health and Human Services (HHS) to conduct various studies on rare kidney disease. Specifically, it authorizes the National Institute of Diabetes and Digestive and Kidney Diseases to award funding to public and private nonprofit entities for establishing regional centers of excellence that will increase public awareness, conduct research, and develop resources for diagnosing and treating rare kidney diseases. A center may receive such funding for up to five years, unless extended by the institute. The bill also requires health professions schools receiving a grant from the Health Resources and Services Administration (HRSA) Centers of Excellence program to award fellowships for training on preventing, diagnosing, and treating rare kidney disease in disproportionately impacted populations. Also, the bill expands the priorities of HRSA’s Primary Care Training and Enhancement program to include training for health care workers to care for individuals with kidney disease. Additionally, HHS must conduct several studies and report to Congress on topics such as treating rare kidney disease in disproportionately affected populations, eliminating the need for dialysis or kidney transplants, and increasing public awareness of rare kidney disease.

Source: BILLSUM · Summary date: 2/24/2025

Related votes

Roll calls that reference this bill in official data.

0 roll calls
No related roll calls found yet for this bill.

Primary sources

Official links to verify details. No interpretation.

About this data

Non-partisan by design
OurCongress presents public records without political endorsement, interpretation, or advocacy.
Official sources
Data is sourced from official government records, including Congress.gov, GovInfo, the Clerk of the House, and the U.S. Senate.
AI-generated text
Some explanatory sections may be generated from official summaries and metadata to improve readability. They are not official government language and should be verified against primary sources.
Last updated: 3/25/2026Source: BILLSUMBill: 119hr1518Learn more →